<?xml version='1.0' encoding='UTF-8'?>
<uniprot xmlns="http://uniprot.org/uniprot" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://uniprot.org/uniprot http://www.uniprot.org/support/docs/uniprot.xsd">
<entry dataset="Swiss-Prot" created="1995-11-01" modified="2017-12-20" version="165">
<accession>P45381</accession>
<name>ACY2_HUMAN</name>
<protein>
<recommendedName>
<fullName>Aspartoacylase</fullName>
<ecNumber evidence="15 16">3.5.1.15</ecNumber>
</recommendedName>
<alternativeName>
<fullName>Aminoacylase-2</fullName>
<shortName>ACY-2</shortName>
</alternativeName>
</protein>
<gene>
<name type="primary">ASPA</name>
<name type="synonym">ACY2</name>
<name type="synonym">ASP</name>
</gene>
<organism>
<name type="scientific">Homo sapiens</name>
<name type="common">Human</name>
<dbReference type="NCBI Taxonomy" id="9606"/>
<lineage>
<taxon>Eukaryota</taxon>
<taxon>Metazoa</taxon>
<taxon>Chordata</taxon>
<taxon>Craniata</taxon>
<taxon>Vertebrata</taxon>
<taxon>Euteleostomi</taxon>
<taxon>Mammalia</taxon>
<taxon>Eutheria</taxon>
<taxon>Euarchontoglires</taxon>
<taxon>Primates</taxon>
<taxon>Haplorrhini</taxon>
<taxon>Catarrhini</taxon>
<taxon>Hominidae</taxon>
<taxon>Homo</taxon>
</lineage>
</organism>
<reference key="1">
<citation type="journal article" date="1993" name="Nat. Genet." volume="5" first="118" last="123">
<title>Cloning of the human aspartoacylase cDNA and a common missense mutation in Canavan disease.</title>
<authorList>
<person name="Kaul R."/>
<person name="Gao G.P."/>
<person name="Balamurugan K."/>
<person name="Matalon R."/>
</authorList>
<dbReference type="PubMed" id="8252036"/>
<dbReference type="DOI" id="10.1038/ng1093-118"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [MRNA]</scope>
<scope>VARIANT CAND ALA-285</scope>
<source>
<tissue>Kidney</tissue>
</source>
</reference>
<reference key="2">
<citation type="journal article" date="2004" name="Genome Res." volume="14" first="2121" last="2127">
<title>The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).</title>
<authorList>
<consortium name="The MGC Project Team"/>
</authorList>
<dbReference type="PubMed" id="15489334"/>
<dbReference type="DOI" id="10.1101/gr.2596504"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]</scope>
<source>
<tissue>Brain</tissue>
</source>
</reference>
<reference key="3">
<citation type="journal article" date="2003" name="Arch. Biochem. Biophys." volume="413" first="1" last="8">
<title>Purification and preliminary characterization of brain aspartoacylase.</title>
<authorList>
<person name="Moore R.A."/>
<person name="Le Coq J."/>
<person name="Faehnle C.R."/>
<person name="Viola R.E."/>
</authorList>
<dbReference type="PubMed" id="12706335"/>
<dbReference type="DOI" id="10.1016/S0003-9861(03)00055-9"/>
</citation>
<scope>CHARACTERIZATION</scope>
<scope>CHARACTERIZATION OF VARIANT CAND ALA-285</scope>
<scope>MUTAGENESIS OF GLU-285</scope>
<source>
<tissue>Brain</tissue>
</source>
</reference>
<reference key="4">
<citation type="journal article" date="2006" name="FEBS Lett." volume="580" first="5899" last="5904">
<title>Identification of the zinc binding ligands and the catalytic residue in human aspartoacylase, an enzyme involved in Canavan disease.</title>
<authorList>
<person name="Herga S."/>
<person name="Berrin J.G."/>
<person name="Perrier J."/>
<person name="Puigserver A."/>
<person name="Giardina T."/>
</authorList>
<dbReference type="PubMed" id="17027983"/>
<dbReference type="DOI" id="10.1016/j.febslet.2006.09.056"/>
</citation>
<scope>CATALYTIC ACTIVITY</scope>
<scope>ZINC-BINDING SITES</scope>
<scope>ACTIVE SITE</scope>
<scope>MUTAGENESIS OF GLU-178</scope>
</reference>
<reference key="5">
<citation type="journal article" date="2008" name="Biochemistry" volume="47" first="3484" last="3492">
<title>Examination of the mechanism of human brain aspartoacylase through the binding of an intermediate analogue.</title>
<authorList>
<person name="Le Coq J."/>
<person name="Pavlovsky A."/>
<person name="Malik R."/>
<person name="Sanishvili R."/>
<person name="Xu C."/>
<person name="Viola R.E."/>
</authorList>
<dbReference type="PubMed" id="18293939"/>
<dbReference type="DOI" id="10.1021/bi702400x"/>
</citation>
<scope>X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) IN COMPLEXES WITH ZINC IONS; PHOSPHATE AND N-PHOSPHONOMETHYL-L-ASPARTATE</scope>
<scope>COFACTOR</scope>
<scope>SUBUNIT</scope>
<scope>MUTAGENESIS OF ARG-71; TYR-164; ARG-168; GLU-178 AND TYR-288</scope>
</reference>
<reference key="6">
<citation type="journal article" date="2007" name="Proc. Natl. Acad. Sci. U.S.A." volume="104" first="456" last="461">
<title>Structure of aspartoacylase, the brain enzyme impaired in Canavan disease.</title>
<authorList>
<person name="Bitto E."/>
<person name="Bingman C.A."/>
<person name="Wesenberg G.E."/>
<person name="McCoy J.G."/>
<person name="Phillips G.N. Jr."/>
</authorList>
<dbReference type="PubMed" id="17194761"/>
<dbReference type="DOI" id="10.1073/pnas.0607817104"/>
</citation>
<scope>X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) IN COMPLEX WITH ZINC IONS</scope>
<scope>SUBUNIT</scope>
<scope>COFACTOR</scope>
</reference>
<reference key="7">
<citation type="journal article" date="1994" name="Am. J. Hum. Genet." volume="55" first="34" last="41">
<title>Canavan disease: mutations among Jewish and non-Jewish patients.</title>
<authorList>
<person name="Kaul R."/>
<person name="Gao G.P."/>
<person name="Aloya M."/>
<person name="Balamurugan K."/>
<person name="Petrosky A."/>
<person name="Michals K."/>
<person name="Matalon R."/>
</authorList>
<dbReference type="PubMed" id="8023850"/>
</citation>
<scope>VARIANTS CAND ALA-285 AND GLU-305</scope>
</reference>
<reference key="8">
<citation type="journal article" date="1995" name="Am. J. Hum. Genet." volume="57" first="572" last="580">
<title>The molecular basis of canavan (aspartoacylase deficiency) disease in European non-Jewish patients.</title>
<authorList>
<person name="Shaag A."/>
<person name="Anikster Y."/>
<person name="Christensen E."/>
<person name="Glustein J.Z."/>
<person name="Fois A."/>
<person name="Michelakakis H."/>
<person name="Nigro F."/>
<person name="Pronicka E."/>
<person name="Ribes A."/>
<person name="Zabot M.-T."/>
<person name="Elpeleg O.N."/>
</authorList>
<dbReference type="PubMed" id="7668285"/>
</citation>
<scope>VARIANTS CAND 176-GLY-ILE-177 DEL; ARG-274; SER-295 AND GLU-305</scope>
</reference>
<reference key="9">
<citation type="journal article" date="1995" name="Hum. Mutat." volume="5" first="269" last="271">
<title>Novel (Cys152 > Arg) missense mutation in an Arab patient with Canavan disease.</title>
<authorList>
<person name="Kaul R."/>
<person name="Gao G.P."/>
<person name="Michals K."/>
<person name="Whelan D.T."/>
<person name="Levin S."/>
<person name="Matalon R."/>
</authorList>
<dbReference type="PubMed" id="7599639"/>
<dbReference type="DOI" id="10.1002/humu.1380050313"/>
</citation>
<scope>VARIANT CAND ARG-152</scope>
</reference>
<reference key="10">
<citation type="journal article" date="1996" name="Am. J. Hum. Genet." volume="59" first="95" last="102">
<title>Identification and expression of eight novel mutations among non-Jewish patients with Canavan disease.</title>
<authorList>
<person name="Kaul R."/>
<person name="Gao G.P."/>
<person name="Matalon R."/>
<person name="Aloya M."/>
<person name="Su Q."/>
<person name="Jin M."/>
<person name="Johnson A.B."/>
<person name="Schutgens R.B.H."/>
<person name="Clarke J.T.R."/>
</authorList>
<dbReference type="PubMed" id="8659549"/>
</citation>
<scope>VARIANTS CAND THR-16; ARG-27; GLU-114; GLU-123; TYR-152; CYS-168; ALA-285 AND GLU-305</scope>
<scope>VARIANT GLY-310</scope>
<scope>CHARACTERIZATION OF VARIANTS CAND THR-16; ARG-27; GLU-114; GLU-123; TYR-152 AND CYS-168</scope>
</reference>
<reference key="11">
<citation type="journal article" date="1998" name="Hum. Mutat. Suppl." volume="1" first="S308" last="S309">
<title>Missense mutation (I143T) in a Japanese patient with Canavan disease.</title>
<authorList>
<person name="Kobayashi K."/>
<person name="Tsujino S."/>
<person name="Ezoe T."/>
<person name="Hamaguchi H."/>
<person name="Nihei K."/>
<person name="Sakuragawa N."/>
</authorList>
<dbReference type="PubMed" id="9452117"/>
</citation>
<scope>VARIANT CAND THR-143</scope>
</reference>
<reference key="12">
<citation type="journal article" date="1999" name="Am. J. Med. Genet." volume="87" first="273" last="275">
<title>Novel missense mutation (Y231C) in a Turkish patient with Canavan disease.</title>
<authorList>
<person name="Rady P.L."/>
<person name="Vargas T."/>
<person name="Tyring S.K."/>
<person name="Matalon R."/>
<person name="Langenbeck U."/>
</authorList>
<dbReference type="PubMed" id="10564886"/>
<dbReference type="DOI" id="10.1002/(SICI)1096-8628(19991126)87:3&lt;273::AID-AJMG17>3.0.CO;2-O"/>
</citation>
<scope>VARIANT CAND CYS-231</scope>
</reference>
<reference key="13">
<citation type="journal article" date="1999" name="J. Inherit. Metab. Dis." volume="22" first="531" last="534">
<title>The spectrum of mutations of the aspartoacylase gene in Canavan disease in non-Jewish patients.</title>
<authorList>
<person name="Elpeleg O.N."/>
<person name="Shaag A."/>
</authorList>
<dbReference type="PubMed" id="10407784"/>
<dbReference type="DOI" id="10.1023/A:1005512524957"/>
</citation>
<scope>VARIANTS CAND THR-16; ARG-27; HIS-183; PHE-186; ARG-195; ARG-274; SER-280; LEU-280; THR-287; SER-295 AND GLU-305</scope>
</reference>
<reference key="14">
<citation type="journal article" date="2000" name="Eur. J. Hum. Genet." volume="8" first="557" last="560">
<title>Mutation detection in the aspartoacylase gene in 17 patients with Canavan disease: four new mutations in the non-Jewish population.</title>
<authorList>
<person name="Sistermans E.A."/>
<person name="de Coo R.F."/>
<person name="van Beerendonk H.M."/>
<person name="Poll-The B.T."/>
<person name="Kleijer W.J."/>
<person name="van Oost B.A."/>
</authorList>
<dbReference type="PubMed" id="10909858"/>
<dbReference type="DOI" id="10.1038/sj.ejhg.5200477"/>
</citation>
<scope>VARIANTS CAND PRO-21; THR-57; HIS-168 AND THR-181</scope>
</reference>
<reference key="15">
<citation type="journal article" date="2002" name="J. Inherit. Metab. Dis." volume="25" first="557" last="570">
<title>Identification and characterization of novel mutations of the aspartoacylase gene in non-Jewish patients with Canavan disease.</title>
<authorList>
<person name="Zeng B.J."/>
<person name="Wang Z.H."/>
<person name="Ribeiro L.A."/>
<person name="Leone P."/>
<person name="De Gasperi R."/>
<person name="Kim S.J."/>
<person name="Raghavan S."/>
<person name="Ong E."/>
<person name="Pastores G.M."/>
<person name="Kolodny E.H."/>
</authorList>
<dbReference type="PubMed" id="12638939"/>
<dbReference type="DOI" id="10.1023/A:1022091223498"/>
</citation>
<scope>VARIANTS CAND GLY-24; ALA-68; TRP-152; ARG-244 AND VAL-249</scope>
</reference>
<reference key="16">
<citation type="journal article" date="2002" name="J. Med. Genet." volume="39" first="E55" last="E55">
<title>Two novel aspartoacylase gene (ASPA) missense mutations specific to Norwegian and Swedish patients with Canavan disease.</title>
<authorList>
<person name="Olsen T.R."/>
<person name="Tranebjaerg L."/>
<person name="Kvittingen E.A."/>
<person name="Hagenfeldt L."/>
<person name="Moller C."/>
<person name="Nilssen O."/>
</authorList>
<dbReference type="PubMed" id="12205125"/>
<dbReference type="DOI" id="10.1136/jmg.39.9.e55"/>
</citation>
<scope>VARIANTS CAND TYR-114 AND VAL-249</scope>
</reference>
<reference key="17">
<citation type="journal article" date="2013" name="Clin. Biochem." volume="46" first="1902" last="1904">
<title>New T530C mutation in the aspartoacylase gene caused Canavan disease with no correlation between severity and N-acetylaspartate excretion.</title>
<authorList>
<person name="Di Pietro V."/>
<person name="Cavallari U."/>
<person name="Amorini A.M."/>
<person name="Lazzarino G."/>
<person name="Longo S."/>
<person name="Poggiani C."/>
<person name="Cavalli P."/>
<person name="Tavazzi B."/>
</authorList>
<dbReference type="PubMed" id="24036223"/>
<dbReference type="DOI" id="10.1016/j.clinbiochem.2013.09.004"/>
</citation>
<scope>VARIANT CAND THR-177</scope>
<scope>CATALYTIC ACTIVITY</scope>
</reference>
<reference key="18">
<citation type="journal article" date="2017" name="Hum. Mutat." volume="38" first="524" last="531">
<title>Clinically distinct phenotypes of Canavan disease correlate with residual aspartoacylase enzyme activity.</title>
<authorList>
<person name="Mendes M.I."/>
<person name="Smith D.E."/>
<person name="Pop A."/>
<person name="Lennertz P."/>
<person name="Fernandez Ojeda M.R."/>
<person name="Kanhai W.A."/>
<person name="van Dooren S.J."/>
<person name="Anikster Y."/>
<person name="Baric I."/>
<person name="Boelen C."/>
<person name="Campistol J."/>
<person name="de Boer L."/>
<person name="Kariminejad A."/>
<person name="Kayserili H."/>
<person name="Roubertie A."/>
<person name="Verbruggen K.T."/>
<person name="Vianey-Saban C."/>
<person name="Williams M."/>
<person name="Salomons G.S."/>
</authorList>
<dbReference type="PubMed" id="28101991"/>
<dbReference type="DOI" id="10.1002/humu.23181"/>
</citation>
<scope>VARIANTS CAND LYS-24; PRO-30; VAL-57; THR-63; ARG-69; VAL-101; LYS-129; THR-170; VAL-180; HIS-204; ARG-248 AND ASP-286</scope>
<scope>CHARACTERIZATION OF VARIANTS CAND LYS-24; PRO-30; VAL-57; THR-63; ARG-69; VAL-101; LYS-129; THR-170; VAL-180; HIS-204; ARG-248; ALA-285 AND ASP-286</scope>
<scope>CATALYTIC ACTIVITY</scope>
<scope>BIOPHYSICOCHEMICAL PROPERTIES</scope>
</reference>
<comment type="function">
<text>Catalyzes the deacetylation of N-acetylaspartic acid (NAA) to produce acetate and L-aspartate. NAA occurs in high concentration in brain and its hydrolysis NAA plays a significant part in the maintenance of intact white matter. In other tissues it act as a scavenger of NAA from body fluids.</text>
</comment>
<comment type="catalytic activity">
<text evidence="12 15 16">N-acyl-L-aspartate + H(2)O = a carboxylate + L-aspartate.</text>
</comment>
<comment type="cofactor">
<cofactor evidence="13 14">
<name>Zn(2+)</name>
<dbReference type="ChEBI" id="CHEBI:29105"/>
</cofactor>
<text evidence="13 14">Binds 1 zinc ion per subunit.</text>
</comment>
<comment type="biophysicochemical properties">
<kinetics>
<Vmax evidence="16">1.2 nmol/h/mg enzyme</Vmax>
</kinetics>
</comment>
<comment type="subunit">
<text evidence="24 25">Homodimer.</text>
</comment>
<comment type="interaction">
<interactant intactId="EBI-750475"/>
<interactant intactId="EBI-750475"/>
<organismsDiffer>false</organismsDiffer>
<experiments>2</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-750475"/>
<interactant intactId="EBI-3916242">
<id>Q96HD9</id>
<label>ACY3</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>9</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-750475"/>
<interactant intactId="EBI-1054321">
<id>Q68J44</id>
<label>DUPD1</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>4</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-750475"/>
<interactant intactId="EBI-751001">
<id>Q14145</id>
<label>KEAP1</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>4</experiments>
</comment>
<comment type="subcellular location">
<subcellularLocation>
<location>Cytoplasm</location>
</subcellularLocation>
<subcellularLocation>
<location evidence="5">Nucleus</location>
</subcellularLocation>
</comment>
<comment type="tissue specificity">
<text>Brain white matter, skeletal muscle, kidney, adrenal glands, lung and liver.</text>
</comment>
<comment type="disease" evidence="6 7 8 9 10 11 15 16 17 18 19 20 21 22">
<disease id="DI-00208">
<name>Canavan disease</name>
<acronym>CAND</acronym>
<description>A rare neurodegenerative condition of infancy or childhood characterized by white matter vacuolization and demyelination that gives rise to a spongy appearance. The clinical features are onset in early infancy, atonia of neck muscles, hypotonia, hyperextension of legs and flexion of arms, blindness, severe mental defect, megalocephaly, and death by 18 months on the average.</description>
<dbReference type="MIM" id="271900"/>
</disease>
<text>The disease is caused by mutations affecting the gene represented in this entry.</text>
</comment>
<comment type="similarity">
<text evidence="23">Belongs to the AspA/AstE family. Aspartoacylase subfamily.</text>
</comment>
<dbReference type="EC" id="3.5.1.15" evidence="15 16"/>
<dbReference type="EMBL" id="S67156">
<property type="protein sequence ID" value="AAB29190.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="BC029128">
<property type="protein sequence ID" value="AAH29128.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="CCDS" id="CCDS11028.1"/>
<dbReference type="PIR" id="S38538">
<property type="entry name" value="S38538"/>
</dbReference>
<dbReference type="RefSeq" id="NP_000040.1">
<property type="nucleotide sequence ID" value="NM_000049.2"/>
</dbReference>
<dbReference type="RefSeq" id="NP_001121557.1">
<property type="nucleotide sequence ID" value="NM_001128085.1"/>
</dbReference>
<dbReference type="RefSeq" id="XP_016880150.1">
<property type="nucleotide sequence ID" value="XM_017024661.1"/>
</dbReference>
<dbReference type="UniGene" id="Hs.171142"/>
<dbReference type="PDB" id="2I3C">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.80"/>
<property type="chains" value="A/B=2-313"/>
</dbReference>
<dbReference type="PDB" id="2O4H">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.70"/>
<property type="chains" value="A/B=1-313"/>
</dbReference>
<dbReference type="PDB" id="2O53">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.70"/>
<property type="chains" value="A/B=1-313"/>
</dbReference>
<dbReference type="PDB" id="2Q51">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.80"/>
<property type="chains" value="A/B=2-313"/>
</dbReference>
<dbReference type="PDB" id="4MRI">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.80"/>
<property type="chains" value="A/B=1-313"/>
</dbReference>
<dbReference type="PDB" id="4MXU">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.60"/>
<property type="chains" value="A/B=1-313"/>
</dbReference>
<dbReference type="PDB" id="4NFR">
<property type="method" value="X-ray"/>
<property type="resolution" value="3.00"/>
<property type="chains" value="A/B=1-313"/>
</dbReference>
<dbReference type="PDB" id="4TNU">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.90"/>
<property type="chains" value="A/B=1-313"/>
</dbReference>
<dbReference type="PDBsum" id="2I3C"/>
<dbReference type="PDBsum" id="2O4H"/>
<dbReference type="PDBsum" id="2O53"/>
<dbReference type="PDBsum" id="2Q51"/>
<dbReference type="PDBsum" id="4MRI"/>
<dbReference type="PDBsum" id="4MXU"/>
<dbReference type="PDBsum" id="4NFR"/>
<dbReference type="PDBsum" id="4TNU"/>
<dbReference type="ProteinModelPortal" id="P45381"/>
<dbReference type="SMR" id="P45381"/>
<dbReference type="BioGrid" id="106935">
<property type="interactions" value="5"/>
</dbReference>
<dbReference type="DIP" id="DIP-60793N"/>
<dbReference type="IntAct" id="P45381">
<property type="interactions" value="3"/>
</dbReference>
<dbReference type="MINT" id="MINT-1440951"/>
<dbReference type="STRING" id="9606.ENSP00000263080"/>
<dbReference type="DrugBank" id="DB00128">
<property type="generic name" value="L-Aspartic Acid"/>
</dbReference>
<dbReference type="iPTMnet" id="P45381"/>
<dbReference type="PhosphoSitePlus" id="P45381"/>
<dbReference type="BioMuta" id="ASPA"/>
<dbReference type="PaxDb" id="P45381"/>
<dbReference type="PeptideAtlas" id="P45381"/>
<dbReference type="PRIDE" id="P45381"/>
<dbReference type="DNASU" id="443"/>
<dbReference type="Ensembl" id="ENST00000263080">
<property type="protein sequence ID" value="ENSP00000263080"/>
<property type="gene ID" value="ENSG00000108381"/>
</dbReference>
<dbReference type="Ensembl" id="ENST00000456349">
<property type="protein sequence ID" value="ENSP00000409976"/>
<property type="gene ID" value="ENSG00000108381"/>
</dbReference>
<dbReference type="GeneID" id="443"/>
<dbReference type="KEGG" id="hsa:443"/>
<dbReference type="CTD" id="443"/>
<dbReference type="DisGeNET" id="443"/>
<dbReference type="EuPathDB" id="HostDB:ENSG00000108381.10"/>
<dbReference type="GeneCards" id="ASPA"/>
<dbReference type="GeneReviews" id="ASPA"/>
<dbReference type="HGNC" id="HGNC:756">
<property type="gene designation" value="ASPA"/>
</dbReference>
<dbReference type="HPA" id="HPA022142"/>
<dbReference type="HPA" id="HPA022145"/>
<dbReference type="MalaCards" id="ASPA"/>
<dbReference type="MIM" id="271900">
<property type="type" value="phenotype"/>
</dbReference>
<dbReference type="MIM" id="608034">
<property type="type" value="gene"/>
</dbReference>
<dbReference type="neXtProt" id="NX_P45381"/>
<dbReference type="OpenTargets" id="ENSG00000108381"/>
<dbReference type="Orphanet" id="314918">
<property type="disease" value="Mild Canavan disease"/>
</dbReference>
<dbReference type="Orphanet" id="314911">
<property type="disease" value="Severe Canavan disease"/>
</dbReference>
<dbReference type="PharmGKB" id="PA25055"/>
<dbReference type="eggNOG" id="ENOG410IERR">
<property type="taxonomic scope" value="Eukaryota"/>
</dbReference>
<dbReference type="eggNOG" id="COG2988">
<property type="taxonomic scope" value="LUCA"/>
</dbReference>
<dbReference type="GeneTree" id="ENSGT00390000001189"/>
<dbReference type="HOGENOM" id="HOG000232489"/>
<dbReference type="HOVERGEN" id="HBG004172"/>
<dbReference type="InParanoid" id="P45381"/>
<dbReference type="KO" id="K01437"/>
<dbReference type="OMA" id="VYKIMEK"/>
<dbReference type="OrthoDB" id="EOG091G0BL6"/>
<dbReference type="PhylomeDB" id="P45381"/>
<dbReference type="TreeFam" id="TF328708"/>
<dbReference type="BioCyc" id="MetaCyc:HS03094-MONOMER"/>
<dbReference type="BRENDA" id="3.5.1.15">
<property type="organism ID" value="2681"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-70614">
<property type="pathway name" value="Amino acid synthesis and interconversion (transamination)"/>
</dbReference>
<dbReference type="EvolutionaryTrace" id="P45381"/>
<dbReference type="GenomeRNAi" id="443"/>
<dbReference type="PRO" id="PR:P45381"/>
<dbReference type="Proteomes" id="UP000005640">
<property type="component" value="Chromosome 17"/>
</dbReference>
<dbReference type="Bgee" id="ENSG00000108381"/>
<dbReference type="CleanEx" id="HS_ASPA"/>
<dbReference type="ExpressionAtlas" id="P45381">
<property type="expression patterns" value="baseline and differential"/>
</dbReference>
<dbReference type="Genevisible" id="P45381">
<property type="organism ID" value="HS"/>
</dbReference>
<dbReference type="GO" id="GO:0005829">
<property type="term" value="C:cytosol"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="HPA"/>
</dbReference>
<dbReference type="GO" id="GO:0070062">
<property type="term" value="C:extracellular exosome"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0005634">
<property type="term" value="C:nucleus"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="UniProtKB-SubCell"/>
</dbReference>
<dbReference type="GO" id="GO:0004046">
<property type="term" value="F:aminoacylase activity"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="ProtInc"/>
</dbReference>
<dbReference type="GO" id="GO:0019807">
<property type="term" value="F:aspartoacylase activity"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0016788">
<property type="term" value="F:hydrolase activity, acting on ester bonds"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="InterPro"/>
</dbReference>
<dbReference type="GO" id="GO:0042802">
<property type="term" value="F:identical protein binding"/>
<property type="evidence" value="ECO:0000353"/>
<property type="project" value="IntAct"/>
</dbReference>
<dbReference type="GO" id="GO:0046872">
<property type="term" value="F:metal ion binding"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="UniProtKB-KW"/>
</dbReference>
<dbReference type="GO" id="GO:0006533">
<property type="term" value="P:aspartate catabolic process"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="ProtInc"/>
</dbReference>
<dbReference type="GO" id="GO:0008652">
<property type="term" value="P:cellular amino acid biosynthetic process"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0022010">
<property type="term" value="P:central nervous system myelination"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0048714">
<property type="term" value="P:positive regulation of oligodendrocyte differentiation"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="CDD" id="cd06909">
<property type="entry name" value="M14_ASPA"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="HAMAP" id="MF_00704">
<property type="entry name" value="Aspartoacylase"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="InterPro" id="IPR016708">
<property type="entry name" value="Aspartoacylase"/>
</dbReference>
<dbReference type="InterPro" id="IPR007036">
<property type="entry name" value="Aste_AspA"/>
</dbReference>
<dbReference type="Pfam" id="PF04952">
<property type="entry name" value="AstE_AspA"/>
<property type="match status" value="1"/>
</dbReference>
<dbReference type="PIRSF" id="PIRSF018001">
<property type="entry name" value="Aspartoacylase"/>
<property type="match status" value="1"/>
</dbReference>
<proteinExistence type="evidence at protein level"/>
<keyword id="KW-0002">3D-structure</keyword>
<keyword id="KW-0181">Complete proteome</keyword>
<keyword id="KW-0963">Cytoplasm</keyword>
<keyword id="KW-0225">Disease mutation</keyword>
<keyword id="KW-0378">Hydrolase</keyword>
<keyword id="KW-1026">Leukodystrophy</keyword>
<keyword id="KW-0479">Metal-binding</keyword>
<keyword id="KW-0539">Nucleus</keyword>
<keyword id="KW-1185">Reference proteome</keyword>
<keyword id="KW-0862">Zinc</keyword>
<feature type="chain" description="Aspartoacylase" id="PRO_0000216871">
<location>
<begin position="1"/>
<end position="313"/>
</location>
</feature>
<feature type="region of interest" description="Substrate binding">
<location>
<begin position="70"/>
<end position="71"/>
</location>
</feature>
<feature type="region of interest" description="Substrate binding">
<location>
<begin position="164"/>
<end position="168"/>
</location>
</feature>
<feature type="active site" evidence="12">
<location>
<position position="178"/>
</location>
</feature>
<feature type="metal ion-binding site" description="Zinc">
<location>
<position position="21"/>
</location>
</feature>
<feature type="metal ion-binding site" description="Zinc">
<location>
<position position="24"/>
</location>
</feature>
<feature type="metal ion-binding site" description="Zinc">
<location>
<position position="116"/>
</location>
</feature>
<feature type="binding site" description="Substrate">
<location>
<position position="63"/>
</location>
</feature>
<feature type="binding site" description="Substrate">
<location>
<position position="178"/>
</location>
</feature>
<feature type="binding site" description="Substrate">
<location>
<position position="288"/>
</location>
</feature>
<feature type="sequence variant" description="In CAND; &lt;0.5% residual enzyme activity; dbSNP:rs769653717." id="VAR_039079" evidence="6 21">
<original>I</original>
<variation>T</variation>
<location>
<position position="16"/>
</location>
</feature>
<feature type="sequence variant" description="In CAND." id="VAR_016778" evidence="8">
<original>H</original>
<variation>P</variation>
<location>
<position position="21"/>
</location>
</feature>
<feature type="sequence variant" description="In CAND; dbSNP:rs104894551." id="VAR_016782" evidence="10">
<original>E</original>
<variation>G</variation>
<location>
<position position="24"/>
</location>
</feature>
<feature type="sequence variant" description="In CAND; &lt;1% residual enzyme activity." id="VAR_078086" evidence="16">
<original>E</original>
<variation>K</variation>
<location>
<position position="24"/>
</location>
</feature>
<feature type="sequence variant" description="In CAND; 3% residual enzyme activity; dbSNP:rs766328537." id="VAR_039080" evidence="6 21">
<original>G</original>
<variation>R</variation>
<location>
<position position="27"/>
</location>
</feature>
<feature type="sequence variant" description="In CAND; &lt;1% residual enzyme activity." id="VAR_078087" evidence="16">
<original>L</original>
<variation>P</variation>
<location>
<position position="30"/>
</location>
</feature>
<feature type="sequence variant" description="In CAND." id="VAR_016779" evidence="8">
<original>A</original>
<variation>T</variation>
<location>
<position position="57"/>
</location>
</feature>
<feature type="sequence variant" description="In CAND; &lt;1% residual enzyme activity." id="VAR_078088" evidence="16">
<original>A</original>
<variation>V</variation>
<location>
<position position="57"/>
</location>
</feature>
<feature type="sequence variant" description="In CAND; &lt;1% residual enzyme activity." id="VAR_078089" evidence="16">
<original>R</original>
<variation>T</variation>
<location>
<position position="63"/>
</location>
</feature>
<feature type="sequence variant" description="In CAND." id="VAR_016783" evidence="10">
<original>D</original>
<variation>A</variation>
<location>
<position position="68"/>
</location>
</feature>
<feature type="sequence variant" description="In CAND; &lt;1% residual enzyme activity; dbSNP:rs776777887." id="VAR_078090" evidence="16">
<original>L</original>
<variation>R</variation>
<location>
<position position="69"/>
</location>
</feature>
<feature type="sequence variant" description="In CAND; &lt;1% residual enzyme activity." id="VAR_078091" evidence="16">
<original>G</original>
<variation>V</variation>
<location>
<position position="101"/>
</location>
</feature>
<feature type="sequence variant" description="In CAND; &lt;0.5% residual enzyme activity." id="VAR_039081" evidence="21">
<original>D</original>
<variation>E</variation>
<location>
<position position="114"/>
</location>
</feature>
<feature type="sequence variant" description="In CAND." id="VAR_016784" evidence="9">
<original>D</original>
<variation>Y</variation>
<location>
<position position="114"/>
</location>
</feature>
<feature type="sequence variant" description="In CAND; about 25% residual enzyme activity." id="VAR_039082" evidence="21">
<original>G</original>
<variation>E</variation>
<location>
<position position="123"/>
</location>
</feature>
<feature type="sequence variant" description="In CAND; &lt;1% residual enzyme activity; dbSNP:rs773049803." id="VAR_078092" evidence="16">
<original>E</original>
<variation>K</variation>
<location>
<position position="129"/>
</location>
</feature>
<feature type="sequence variant" description="In CAND; dbSNP:rs777936704." id="VAR_004995" evidence="22">
<original>I</original>
<variation>T</variation>
<location>
<position position="143"/>
</location>
</feature>
<feature type="sequence variant" description="In CAND; loss of activity; dbSNP:rs104894548." id="VAR_004996" evidence="17">
<original>C</original>
<variation>R</variation>
<location>
<position position="152"/>
</location>
</feature>
<feature type="sequence variant" description="In CAND." id="VAR_016785" evidence="10">
<original>C</original>
<variation>W</variation>
<location>
<position position="152"/>
</location>
</feature>
<feature type="sequence variant" description="In CAND; &lt;0.5% residual enzyme activity." id="VAR_039083" evidence="21">
<original>C</original>
<variation>Y</variation>
<location>
<position position="152"/>
</location>
</feature>
<feature type="sequence variant" description="In CAND; undetectable enzyme activity; dbSNP:rs937670540." id="VAR_039084" evidence="21">
<original>R</original>
<variation>C</variation>
<location>
<position position="168"/>
</location>
</feature>
<feature type="sequence variant" description="In CAND; dbSNP:rs770706390." id="VAR_016780" evidence="8">
<original>R</original>
<variation>H</variation>
<location>
<position position="168"/>
</location>
</feature>
<feature type="sequence variant" description="In CAND; 5.5% residual enzyme activity; dbSNP:rs144321760." id="VAR_078093" evidence="16">
<original>I</original>
<variation>T</variation>
<location>
<position position="170"/>
</location>
</feature>
<feature type="sequence variant" description="In CAND." id="VAR_004997" evidence="18">
<location>
<begin position="176"/>
<end position="177"/>
</location>
</feature>
<feature type="sequence variant" description="In CAND; Loss of catalytic activity." id="VAR_078094" evidence="15">
<original>I</original>
<variation>T</variation>
<location>
<position position="177"/>
</location>
</feature>
<feature type="sequence variant" description="In CAND; &lt;1% residual enzyme activity; dbSNP:rs1014551540." id="VAR_078095" evidence="16">
<original>G</original>
<variation>V</variation>
<location>
<position position="180"/>
</location>
</feature>
<feature type="sequence variant" description="In CAND; dbSNP:rs786204572." id="VAR_016781" evidence="8">
<original>P</original>
<variation>T</variation>
<location>
<position position="181"/>
</location>
</feature>
<feature type="sequence variant" description="In CAND." id="VAR_039085" evidence="6">
<original>P</original>
<variation>H</variation>
<location>
<position position="183"/>
</location>
</feature>
<feature type="sequence variant" description="In CAND." id="VAR_039086" evidence="6">
<original>V</original>
<variation>F</variation>
<location>
<position position="186"/>
</location>
</feature>
<feature type="sequence variant" description="In CAND." id="VAR_039087" evidence="6">
<original>M</original>
<variation>R</variation>
<location>
<position position="195"/>
</location>
</feature>
<feature type="sequence variant" description="In CAND; 12% residual enzyme activity." id="VAR_078096" evidence="16">
<original>D</original>
<variation>H</variation>
<location>
<position position="204"/>
</location>
</feature>
<feature type="sequence variant" description="In CAND; dbSNP:rs104894550." id="VAR_016786" evidence="7">
<original>Y</original>
<variation>C</variation>
<location>
<position position="231"/>
</location>
</feature>
<feature type="sequence variant" description="In CAND; dbSNP:rs1057516995." id="VAR_016787" evidence="10">
<original>H</original>
<variation>R</variation>
<location>
<position position="244"/>
</location>
</feature>
<feature type="sequence variant" description="In CAND; &lt;1% residual enzyme activity." id="VAR_078097" evidence="16">
<original>Q</original>
<variation>R</variation>
<location>
<position position="248"/>
</location>
</feature>
<feature type="sequence variant" description="In CAND; dbSNP:rs104894552." id="VAR_016788" evidence="9 10">
<original>D</original>
<variation>V</variation>
<location>
<position position="249"/>
</location>
</feature>
<feature type="sequence variant" description="In CAND; dbSNP:rs761064915." id="VAR_004998" evidence="6 18">
<original>G</original>
<variation>R</variation>
<location>
<position position="274"/>
</location>
</feature>
<feature type="sequence variant" description="In CAND." id="VAR_039088" evidence="6">
<original>P</original>
<variation>L</variation>
<location>
<position position="280"/>
</location>
</feature>
<feature type="sequence variant" description="In CAND; dbSNP:rs750505963." id="VAR_039089" evidence="6">
<original>P</original>
<variation>S</variation>
<location>
<position position="280"/>
</location>
</feature>
<feature type="sequence variant" description="In CAND; predominant mutation in Ashkenazi Jewish population; 99% loss of activity; dbSNP:rs28940279." id="VAR_004999" evidence="11 16 19 20 21">
<original>E</original>
<variation>A</variation>
<location>
<position position="285"/>
</location>
</feature>
<feature type="sequence variant" description="In CAND; &lt;1% residual enzyme activity." id="VAR_078098" evidence="16">
<original>A</original>
<variation>D</variation>
<location>
<position position="286"/>
</location>
</feature>
<feature type="sequence variant" description="In CAND; dbSNP:rs774323189." id="VAR_039090" evidence="6">
<original>A</original>
<variation>T</variation>
<location>
<position position="287"/>
</location>
</feature>
<feature type="sequence variant" description="In CAND." id="VAR_005000" evidence="6 18">
<original>F</original>
<variation>S</variation>
<location>
<position position="295"/>
</location>
</feature>
<feature type="sequence variant" description="In CAND; pan-European origin; most prevalent among non-Jewish CAND patients; probably the most ancient mutation; loss of activity; dbSNP:rs28940574." id="VAR_005001" evidence="6 18 19 21">
<original>A</original>
<variation>E</variation>
<location>
<position position="305"/>
</location>
</feature>
<feature type="sequence variant" description="In dbSNP:rs376854191." id="VAR_039091" evidence="21">
<original>C</original>
<variation>G</variation>
<location>
<position position="310"/>
</location>
</feature>
<feature type="mutagenesis site" description="Reduces activity by 99%." evidence="14">
<original>R</original>
<variation>K</variation>
<location>
<position position="71"/>
</location>
</feature>
<feature type="mutagenesis site" description="Reduces activity by 99%." evidence="14">
<original>Y</original>
<variation>F</variation>
<location>
<position position="164"/>
</location>
</feature>
<feature type="mutagenesis site" description="Reduces activity by 99%." evidence="14">
<original>R</original>
<variation>K</variation>
<location>
<position position="168"/>
</location>
</feature>
<feature type="mutagenesis site" description="Reduces activity by 99%." evidence="12 14">
<original>E</original>
<variation>A</variation>
<location>
<position position="178"/>
</location>
</feature>
<feature type="mutagenesis site" description="Abolishes enzymatic activity." evidence="12 14">
<original>E</original>
<variation>D</variation>
<location>
<position position="178"/>
</location>
</feature>
<feature type="mutagenesis site" description="Abolishes enzymatic activity." evidence="12 14">
<original>E</original>
<variation>Q</variation>
<location>
<position position="178"/>
</location>
</feature>
<feature type="mutagenesis site" description="5-fold decrease in activity." evidence="11">
<original>E</original>
<variation>D</variation>
<location>
<position position="285"/>
</location>
</feature>
<feature type="mutagenesis site" description="Reduces activity by 99%." evidence="14">
<original>Y</original>
<variation>F</variation>
<location>
<position position="288"/>
</location>
</feature>
<feature type="strand" evidence="3">
<location>
<begin position="14"/>
<end position="18"/>
</location>
</feature>
<feature type="helix" evidence="3">
<location>
<begin position="25"/>
<end position="34"/>
</location>
</feature>
<feature type="helix" evidence="3">
<location>
<begin position="39"/>
<end position="41"/>
</location>
</feature>
<feature type="strand" evidence="3">
<location>
<begin position="48"/>
<end position="53"/>
</location>
</feature>
<feature type="helix" evidence="3">
<location>
<begin position="55"/>
<end position="59"/>
</location>
</feature>
<feature type="strand" evidence="3">
<location>
<begin position="65"/>
<end position="67"/>
</location>
</feature>
<feature type="helix" evidence="3">
<location>
<begin position="69"/>
<end position="71"/>
</location>
</feature>
<feature type="helix" evidence="3">
<location>
<begin position="75"/>
<end position="78"/>
</location>
</feature>
<feature type="strand" evidence="4">
<location>
<begin position="84"/>
<end position="86"/>
</location>
</feature>
<feature type="helix" evidence="3">
<location>
<begin position="88"/>
<end position="100"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="105"/>
<end position="108"/>
</location>
</feature>
<feature type="strand" evidence="3">
<location>
<begin position="110"/>
<end position="117"/>
</location>
</feature>
<feature type="strand" evidence="3">
<location>
<begin position="119"/>
<end position="121"/>
</location>
</feature>
<feature type="strand" evidence="3">
<location>
<begin position="123"/>
<end position="129"/>
</location>
</feature>
<feature type="helix" evidence="3">
<location>
<begin position="134"/>
<end position="147"/>
</location>
</feature>
<feature type="strand" evidence="3">
<location>
<begin position="152"/>
<end position="156"/>
</location>
</feature>
<feature type="strand" evidence="1">
<location>
<begin position="160"/>
<end position="162"/>
</location>
</feature>
<feature type="helix" evidence="3">
<location>
<begin position="167"/>
<end position="170"/>
</location>
</feature>
<feature type="strand" evidence="3">
<location>
<begin position="171"/>
<end position="181"/>
</location>
</feature>
<feature type="helix" evidence="3">
<location>
<begin position="189"/>
<end position="210"/>
</location>
</feature>
<feature type="strand" evidence="3">
<location>
<begin position="218"/>
<end position="229"/>
</location>
</feature>
<feature type="strand" evidence="3">
<location>
<begin position="237"/>
<end position="239"/>
</location>
</feature>
<feature type="strand" evidence="2">
<location>
<begin position="241"/>
<end position="243"/>
</location>
</feature>
<feature type="turn" evidence="3">
<location>
<begin position="245"/>
<end position="249"/>
</location>
</feature>
<feature type="strand" evidence="3">
<location>
<begin position="259"/>
<end position="263"/>
</location>
</feature>
<feature type="strand" evidence="3">
<location>
<begin position="269"/>
<end position="271"/>
</location>
</feature>
<feature type="strand" evidence="3">
<location>
<begin position="274"/>
<end position="276"/>
</location>
</feature>
<feature type="strand" evidence="3">
<location>
<begin position="278"/>
<end position="282"/>
</location>
</feature>
<feature type="helix" evidence="3">
<location>
<begin position="286"/>
<end position="288"/>
</location>
</feature>
<feature type="turn" evidence="3">
<location>
<begin position="289"/>
<end position="292"/>
</location>
</feature>
<feature type="strand" evidence="3">
<location>
<begin position="294"/>
<end position="305"/>
</location>
</feature>
<evidence key="1" type="ECO:0000244">
<source>
<dbReference type="PDB" id="2O4H"/>
</source>
</evidence>
<evidence key="2" type="ECO:0000244">
<source>
<dbReference type="PDB" id="2O53"/>
</source>
</evidence>
<evidence key="3" type="ECO:0000244">
<source>
<dbReference type="PDB" id="4MXU"/>
</source>
</evidence>
<evidence key="4" type="ECO:0000244">
<source>
<dbReference type="PDB" id="4TNU"/>
</source>
</evidence>
<evidence key="5" type="ECO:0000250"/>
<evidence key="6" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="10407784"/>
</source>
</evidence>
<evidence key="7" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="10564886"/>
</source>
</evidence>
<evidence key="8" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="10909858"/>
</source>
</evidence>
<evidence key="9" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="12205125"/>
</source>
</evidence>
<evidence key="10" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="12638939"/>
</source>
</evidence>
<evidence key="11" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="12706335"/>
</source>
</evidence>
<evidence key="12" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="17027983"/>
</source>
</evidence>
<evidence key="13" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="17194761"/>
</source>
</evidence>
<evidence key="14" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="18293939"/>
</source>
</evidence>
<evidence key="15" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="24036223"/>
</source>
</evidence>
<evidence key="16" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="28101991"/>
</source>
</evidence>
<evidence key="17" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="7599639"/>
</source>
</evidence>
<evidence key="18" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="7668285"/>
</source>
</evidence>
<evidence key="19" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="8023850"/>
</source>
</evidence>
<evidence key="20" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="8252036"/>
</source>
</evidence>
<evidence key="21" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="8659549"/>
</source>
</evidence>
<evidence key="22" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="9452117"/>
</source>
</evidence>
<evidence key="23" type="ECO:0000305"/>
<evidence key="24" type="ECO:0000305">
<source>
<dbReference type="PubMed" id="17194761"/>
</source>
</evidence>
<evidence key="25" type="ECO:0000305">
<source>
<dbReference type="PubMed" id="18293939"/>
</source>
</evidence>
<sequence length="313" mass="35735" checksum="33C0B9B07839E7F5" modified="1995-11-01" version="1">
MTSCHIAEEHIQKVAIFGGTHGNELTGVFLVKHWLENGAEIQRTGLEVKPFITNPRAVKK
CTRYIDCDLNRIFDLENLGKKMSEDLPYEVRRAQEINHLFGPKDSEDSYDIIFDLHNTTS
NMGCTLILEDSRNNFLIQMFHYIKTSLAPLPCYVYLIEHPSLKYATTRSIAKYPVGIEVG
PQPQGVLRADILDQMRKMIKHALDFIHHFNEGKEFPPCAIEVYKIIEKVDYPRDENGEIA
AIIHPNLQDQDWKPLHPGDPMFLTLDGKTIPLGGDCTVYPVFVNEAAYYEKKEAFAKTTK
LTLNAKSIRCCLH
</sequence>
</entry>
<copyright>
Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
Distributed under the Creative Commons Attribution-NoDerivs License
</copyright>
</uniprot>